Journal of Medical Cases, ISSN 1923-4155 print, 1923-4163 online, Open Access |
Article copyright, the authors; Journal compilation copyright, J Med Cases and Elmer Press Inc |
Journal website https://jmc.elmerpub.com/ |
Case Report
Volume 15, Number 12, December 2024, pages 387-395
Exploring Overlap Syndromes: An Atypical Case of Multiple Sclerosis With Anti-Sjogren’s Syndrome Type B Antibody
Figures
Tables
Evaluations | Value (normal range) |
---|---|
aAbnormal results. Ig: immunoglobulin; Ab: antibody; CSF: cerebrospinal fluid; IFA: immunofluorescence assay; ANNA: anti-neuronal nuclear antibody; PCA: Purkinje cell antibody; DNER: delta/notch-like EGF-related receptor; AGNA/SOX1: anti-glial nuclear antibody/anti-SRY (sex determining region Y)-box 1; CRMP5/CV2: collapsin response mediator protein 5 (also known as “CV2”); MPO: myeloperoxidase; PR3: proteinase 3; C-ANCA: cytoplasmic antineutrophil cytoplasmic antibodies; P-ANCA: perinuclear antineutrophil cytoplasmic antibodies; MOG: myelin oligodendrocyte glycoprotein; SSA: Sjogren’s syndrome type A (also known as anti-Ro); SSB: Sjogren’s syndrome type B (also known as anti-La); CCP: cyclic citrullinated peptide; Rnp: ribonucleoprotein; CSF: cerebrospinal fluid; RBC: red blood cell; WBC: white blood cell; VDRL: venereal disease research laboratory test; GAD65: glutamic acid decarboxylase 65; AI: antibody index; EU: endotoxin units; APL-U: IgA phospholipid units; GPL-U: IgG phospholipid units; MPL-U: IgM phospholipid units. | |
Serum evaluation | |
IgA level | 259.45 (84.5 - 499 mg/dL) |
IgG level | 764.35 (610.3 - 1,616 mg/dL) |
IgM level | 155.25 (35 - 242 mg/dL) |
Tissue IFA observation | No fluorescence observed |
ANNA1 (HU) Ab, IFA | Negative |
ANN2 (R1) Ab, IFA | Negative |
ANNA3 Ab, IFA | Negative |
PCA1 (YO) Ab, IFA | Negative |
PCA2 Ab, IFA | Negative |
PCA TR (DNER) Ab, IFA | Negative |
AGNA/SOX1 Ab, IFA | Negative |
AMPHIPHYSIN Ab, IFA | Negative |
CRMP5/CV2 Ab, IFA | Negative |
Aquaporin 4 Ab (IgG) | Negative |
Anti-MPO Ab | < 0.2 (0.0 - 0.9 U) |
Anti-PR3 Ab | < 0.2 (0.0 - 0.9 U) |
C-ANCA | < 1:20 |
P-ANCA | < 1:20 |
Atypical P-ANCA | < 1:20 |
Lyme total Ab | Negative |
MOG Ab, serum | Negative |
Sjogren’s Ab (SSA) | < 0.2 (0.0 - 0.9 AI) |
Sjogren’s Ab (SSB) | 2.7, 2.8 (0.0 - 0.9 AI)a |
Ribosomal P Ab | < 0.2 (0.0 - 0.9 AI) |
Salivary protein 1 IgG Ab | 2.6 (< 20 EU/mL) |
Salivary protein 1 IgA Ab | 2.0 (< 20 EU/mL) |
Salivary protein 1 IgM Ab | 74.2 (< 20 EU/mL)a |
Carbonic anhydrase VI IgG Ab | > 160.0 (< 20 EU/mL)a |
Carbonic anhydrase VI IgA Ab | 87.0 (< 20 EU/mL)a |
Carbonic anhydrase VI IgM Ab | 17.2 (< 20 EU/mL) |
Parotid specific protein IgG Ab | 18.2 (< 20 EU/mL) |
Parotid specific protein IgA Ab | 27.4 (< 20 EU/mL)a |
Parotid specific protein IgM Ab | 22.0 (< 20 EU/mL; borderline: 20 - 25 EU/mL) |
Cyclic citrullinated peptide (CCP) Ab IgG | < 16 (< 20) |
Lupus anticoagulant | Not detected |
Rheumatoid factor | < 14 (< 14 IU/mL) |
Cardiolipin Ab, IgA | < 2.0 (< 20 APL-U/mL) |
Cardiolipin Ab, IgG | < 2.0 (< 20 GPL-U/mL) |
Cardiolipin Ab, IgM | < 2.0 (< 20 MPL-U/mL) |
Beta-2 glycoprotein I Ab, IgM | < 2.0 (< 20 U/mL) |
Beta-2 glycoprotein I Ab, IgA | < 2.0 (< 20 U/mL) |
Beta-2 glycoprotein I Ab, IgG | < 2.0 (< 20 U/mL) |
Antinuclear Ab, IFA | Negative |
Anti-DNA (Ds) Ab | 3 (0-9 IU/mL) |
Rnp Ab | < 0.2 (0.0 - 0.9 AI) |
Smith Ab | < 0.2 (0.0 - 0.9 AI) |
Scleroderma (Scl-70) Ab | < 0.2 (0.0 - 0.9 AI) |
Oligoclonal bands, serum | 0 |
CSF evaluation | Value (normal range) |
Protein | 24 (15 - 45 mg/dL) |
Glucose | 71 (40 - 75 mg/dL) |
RBC count | 3,100 (0/mm3)a |
WBC count | 8 (0 - 5/mm3)a |
Neutrophils | 34% |
Lymphocytes | 59% |
Monocytes | 6% |
Eosinophils | 1% |
Cryptococcus gattii neoformans DNA CSF | Not detected |
Cytomegalovirus DNA CSF | Not detected |
Enterovirus RNA CSF | Not detected |
Escherichia coli K1 DNA CSF | Not detected |
Haemophilus influenzae DNA CSF | Not detected |
Herpes simplex virus 1 DNA CSF | Not detected |
Herpes simplex virus 2 DNA CSF | Not detected |
Herpes virus 6 DNA CSF | Not detected |
Parechovirus A RNA CSF | Not detected |
Listeria monocytogenes DNA CSF | Not detected |
Neisseria meningitidis DNA CSF | Not detected |
Streptococcus agalactiae DNA CSF | Not detected |
Streptococcus pneumoniae DNA CSF | Not detected |
Varicella zoster virus DNA CSF | Not detected |
VDRL, CSF | Non-reactive |
CRMP5/CV2 AB, IFA, CSF | Negative |
GAD65 antibody, IFA, CSF | Negative |
Aquaporin 4 Ab (IgG), CSF | Negative |
MOG Ab, CSF | Negative |
Oligoclonal bands, CSF | 5 CSF-specific bands |
Flow cytometry analysis | No immunophenotypically abnormal T or B cells detected |
Cytology | Negative for malignancy |
Time point | Clinical findings | Laboratory data | Imaging findings | Treatment |
---|---|---|---|---|
CSF: cerebrospinal fluid; MRI: magnetic resonance imaging; FLAIR: fluid-attenuated inversion recovery; IV: intravenous; SSB: Sjogren’s syndrome B. | ||||
Hospital admission (initial presentation) | Left face and hemibody paresthesias | CSF: mild leukocytosis, 5 CSF-specific oligoclonal bands | MRI brain: T2 FLAIR hyperintensity in the bilateral periventricular regions and right pons; cranial nerve enhancement | 5-day course of high-dose IV methylprednisolone |
Abnormal gait with left leg dragging | Serum: positive anti-SSB antibody; no serum oligoclonal bands | MRI spine: enhancement in the cauda equina and thoracic nerve roots | ||
Weakness in left hip and knee | ||||
Absent lower extremity reflexes | ||||
Hospital discharge (8 days post-admission) | Mild improvement in strength | No new laboratory findings | No new imaging findings | Discharged with follow-up to neuroimmunology and rheumatology |
Persistent left-sided paresthesias | ||||
2 months post-discharge | Improved motor exam | Serum: elevated salivary protein 1 IgM, elevated carbonic anhydrase VI IgG and IgM antibodies, elevated parotid specific protein IgA antibody | MRI brain: persistent enhancement of cranial nerves | 3-day course of high-dose oral prednisone |
Residual numbness | Ofatumumab 20 mg monthly |
Case | Patient | Case presentation | Suspected initial diagnosis | Diagnostic dilemmas and changes | Final diagnosis | Key takeaways |
---|---|---|---|---|---|---|
F: female; BLE: bilateral lower extremity; MS: multiple sclerosis; SSB: Sjogren’s syndrome B; SS: Sjogren’s syndrome; MRI: magnetic resonance imaging; CNS: central nervous system; UCTD: undifferentiated connective tissue disease; IFN: interferon; PBC: primary biliary cholangitis; BUE: bilateral upper extremity; N/A: not available. | ||||||
Our case | F, 39 years | Patient presented with left face and hemibody paresthesias, abnormal gait with left leg dragging, weakness in left hip and knee, and absent BLE reflexes. | MS | Serum studies revealed a positive Sjogren’s anti-SSB antibody, despite no history of systemic or sicca symptoms. | MS and SS overlap | It is important to consider autoimmune overlap conditions in cases where there are atypical neurologic symptoms, as the co-occurrence of MS and SS can impact treatment strategies. |
Mohamednour et al, 2020 [10] | F, 58 years | Patient with a 3-year history of MS presented with polyarthralgia, sicca symptoms, and Raynaud’s. | MS | Initial MRI of the brain and spine were reported as normal with few “nonspecific white matter areas”, complicating the diagnosis. | SS | CNS involvement in SS can closely resemble MS, complicating the diagnosis. Peripheral neuropathy and vasculitis are key differentiators. Early neurophysiological testing is crucial, and effective immunosuppression with shared decision-making can achieve successful outcomes. |
Jung et al, 2000 [11] | F, 45 years | Patient with a 4-year history of dry eyes and mouth presented with BLE weakness, voiding difficulty, decreased visual acuity, BLE spasticity and hyperesthesia, and diffuse hyperreflexia. | MS | Erythematous skin lesions soon developed in the periauricular area and BLE. Skin and salivary gland biopsies both showed lymphocytic infiltration. | SS | SS should be considered as a differential diagnosis of a patient presenting with a syndrome that resembles MS because of the similarity in clinical manifestations and laboratory findings of both diseases. |
Thong et al, 2002 [12] | F, 40 years | Patient with a history of a lacunar stroke with no residual deficits presented with acute urinary retention and diminished sensation below T5 spinal level, followed by a year of episodes of ataxia and upper limb dysmetria, retrobulbar neuritis, and pseudobulbar palsy. | UCTD | Five years after initial neurologic symptoms, the patient presented with pseudobulbar palsy and endorsed 1 year of sicca symptoms. Schirmer test was positive, and anti-Ro antibody was elevated. | SS | Patients with MS-like diseases should be carefully evaluated for other system autoimmune conditions as the treatment and prognosis differ from MS. Particularly, sicca symptoms should be sought as they often go unnoticed by patients. |
De Santi et al, 2005 [13] | F, 48 years | Patient with a 29-year history of MS treated well with IFN-beta 1a for 5 years presented with xerophthalmia and xerostomia with dysphagia. | MS | N/A | MS and SS overlap | SS can develop long after the onset of MS, even during successful IFN-beta treatment. This case highlights the need to monitor MS patients for SS, as symptoms may arise unexpectedly, complicating diagnosis and management. |
Guzel et al, 2022 [14] | F, 51 years | Patient with a history of PBC and Hashimoto thyroiditis presented with numbness and weakness in the left upper and lower extremities; further questioning revealed symptoms of dry eyes and mouth. | MS and SS overlap | N/A | MS and SS overlap | This case highlights the rare coexistence of four autoimmune diseases, emphasizing the importance of considering multiple overlapping autoimmune disorders in complex presentations. |
Liu et al, 2014 [15] | F, 75 years | Patient presented with recurring numbness and sensory changes in BUE and BLE with zonesthesia in the waist. | MS | Patient had subsequent worsening of paresthesias and swelling of the parotid gland; oral and ocular sicca syndromes were suspected from history taking and confirmed by Schirmer test and labial salivary gland biopsies | SS | SS should be considered in the differential diagnosis of patients presenting with MS-like neurological symptoms, as it can mimic MS both clinically and neuroradiologically. |